Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levofloxacin + prednisolone is a fixed-dose combination drug, most commonly formulated as an ophthalmic solution (eye drops), used to treat bacterial infections of the eye and associated inflammation. Levofloxacin is a third-generation fluoroquinolone antibiotic that acts by inhibiting bacterial DNA gyrase, thereby preventing DNA replication and leading to bacterial cell death. Prednisolone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory properties; it works by inhibiting the synthesis of pro-inflammatory mediators such as cytokines and prostaglandins. The combination provides both antibacterial action (from levofloxacin) and anti-inflammatory effects (from prednisolone), making it effective for conditions like post-operative endophthalmitis, acute exacerbations of chronic bronchitis with ocular involvement, community-acquired ocular infections, or other inflammatory/infectious diseases of the eye[2][3][5]. This product is typically developed for topical ophthalmic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levofloxacin + prednisolone.